Search research articles
Contact Us
Filters
Showing results (211-220 of 247) with videos related to
Page
of 25
Sort By:
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens
Mingxuan Xu, Coya Tapia, Joud Hajjar, et al.
Nature Communications
|
September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
Guangchun Han, Guoliang Yang, Dapeng Hao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
Blessie Elizabeth Nelson, Filip Janku, Siqing Fu, et al.
Research Square
|
February 6, 2026
Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors
Nejla Ozirmak Lermi, Mohamed A Gouda, Jibran Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Herbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Open Forum Infectious Diseases
|
August 2, 2021
Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report
Marta Massanella, Anabel Martin-Urda, Lourdes Mateu, et al.
BMC Cancer
|
July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
The Oncologist
|
March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and Equity
Carlos Torrado, Clark R Andersen, Lei Kang, et al.
Nature Cancer
|
February 28, 2022
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, et al.
Radiology
|
January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
Marta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
Page
of 25
Search research articles
Search
Showing results (211-220 of 247) with videos related to
Sort By:
Page
of 25
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens
Mingxuan Xu, Coya Tapia, Joud Hajjar, et al.
Nature Communications
|
September 24, 2021
9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy
Guangchun Han, Guoliang Yang, Dapeng Hao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2025
Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors
Blessie Elizabeth Nelson, Filip Janku, Siqing Fu, et al.
Research Square
|
February 6, 2026
Tumor microenvironment changes after treatment with avelumab and immune- stimulating agent combinations in patients with advanced solid tumors
Nejla Ozirmak Lermi, Mohamed A Gouda, Jibran Ahmed, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2023
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
Herbert L Duvivier, Michael Rothe, Pam K Mangat, et al.
Open Forum Infectious Diseases
|
August 2, 2021
Critical Presentation of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection: A Case Report
Marta Massanella, Anabel Martin-Urda, Lourdes Mateu, et al.
BMC Cancer
|
July 22, 2024
ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
Alexandra Leary, Purificación Estévez-García, Renaud Sabatier, et al.
The Oncologist
|
March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and Equity
Carlos Torrado, Clark R Andersen, Lei Kang, et al.
Nature Cancer
|
February 28, 2022
The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology
David Tamborero, Rodrigo Dienstmann, Maan Haj Rachid, et al.
Radiology
|
January 26, 2021
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors
Marta Ligero, Alonso Garcia-Ruiz, Cristina Viaplana, et al.
Page
of 25